NCT06679465

Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of Saskatchewan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate single dose (2 x 2.5mcg/puff; total dose 5mcg) effect of tiotropium administered 30 minutes prior to allergen challenge on allergen-induced EAR assessed as the maximal % fall in FEV1 after allergen inhalation compared to that of single dose (two puffs) matched placebo administered 30 minutes prior to allergen challenge.

Conditions

• Asthma Bronchiale

Interventions

Type	Name	Description
DRUG	Tiotropium (Spiriva®)	2 puffs tiotropium prior to allergen challenge
DRUG	Placebo	2 puffs placebo

Timeline

• Start date: 2025-01-01
• Primary completion: 2027-01-01
• Completion: 2027-01-01
• First posted: 2024-11-07
• Last updated: 2024-11-07

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study